

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **PW MEDTECH GROUP LIMITED**

### **普 华 和 顺 集 团 公 司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

### **PROFIT ALERT**

This announcement is made by PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and the potential investors that, based on the information currently available to the Board, including the latest unaudited management accounts of the Group for the five months ended May 31, 2020, the Group is expected to record a significant decrease in the revenue from the Group’s infusion set business for the six months ended June 30, 2020 in the range of 35% to 45% as compared with RMB172.3 million for the same period of last year. The Board is of the view that the expected decrease in revenue from the Group’s infusion set business is mainly due to the outbreak of the novel coronavirus (“**COVID-19**”) pandemic starting in early 2020 which has caused significant decline in hospital traffic in some areas in the People’s Republic of China (“**PRC**”) and imposition of travel restrictions in the PRC. The Group has been closely monitoring the market conditions and adjusted its business strategies and operations to minimize the negative impact.

In addition, as disclosed in the announcement dated May 10, 2020 and the circular dated October 18, 2019 of the Company, in light of the estimated one-off gain on the disposal of part of the shares of China Biologic Products Holdings, Inc. completed in May 2020, the Group expects that such one-off gain on disposal will make a substantial contribution to the profit attributable to owners of the Company for the six months ended June 30, 2020.

Notwithstanding the above, the Group is currently unable to reasonably estimate the profit attributable to owners of the Company for the six months ended June 30, 2020 after excluding such one-off gain on disposal, since the performance results of investment in CBPO for the second quarter of 2020 are not available to the Company as of the date of this announcement.

The Board believes that the financial position and cash flow of the Group remain sound and healthy. Barring unforeseen circumstances and subject to factors including the development of the COVID-19 situation in the PRC and the market conditions, the Board currently expects that the revenue of the Group will improve in the second half of 2020 as compared with the first half.

The information contained in this announcement is only based on the preliminary review on the unaudited management accounts of the Group for the five months ended May 31, 2020 and the information currently available, which are subject to finalization and necessary adjustments and have not been confirmed or reviewed by the Company's auditor. Therefore, the actual consolidated results of the Group for the six months ended June 30, 2020, which are expected to be released by the Company in due course, may differ from the information contained in this announcement.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**PW Medtech Group Limited**  
**Yue'e Zhang**  
*Chairman & Chief Executive Officer*

Beijing, July 6, 2020

*As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jaing Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Zhang Xingdong and Mr. Chen Geng.*